Now Enrolling - 50 Model Solid Tumor
PDX In Vivo Screen

Participate in the Champions Oncology PDX Indication Screen for lower cost, large scale
PDX pharmacology studies

50 Clinically Relevant PDX Models - View Characterization Data;
- Breast
- Gastric
- Bladder
- Cholangiocarcinoma
- Hepatocellular Carcinoma

Enrollment Open Now - August 31st - Models available on a first-come first-served basis.

The details on the Champions' Solid Tumor PDX In Vivo Screen are detailed below:
- NGS Data (WES and RNASeq) is freely available for all models
- Free FFPE/Snap frozen samples available at no cost for target validation
  • Significant cost savings compared to stand-alone studies
  • No minimum enrollment
  • Patient treatment history and PDX drug response data available
  • Free terminal tumor collections
  • Flow cytometry, IHC and Nanostring gene expression analysis available
  • Enrollment period ends August 31st, 2019
Please contact Mandy Lehmann today at or +41 78 307 90 55 for more information

Email Marketing by ActiveCampaign